In PhI­II da­ta, Eli Lil­ly’s Retev­mo meets pri­ma­ry end­point of im­prov­ing pro­gres­sion-free sur­vival

Eli Lil­ly’s Retev­mo to treat ad­vanced or metasta­t­ic re­arranged dur­ing trans­fec­tion (RET)-mu­tant medullary thy­roid can­cer (MTC) showed promis­ing re­sults at im­prov­ing pro­gres­sion-free sur­vival com­pared to mul­ti­k­i­nase in­hibitors, in topline da­ta the com­pa­ny re­leased Tues­day.

The LI­BRET­TO-531 tri­al met its pri­ma­ry end­point, show­ing a sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment in pro­gres­sion-free sur­vival, Eli Lil­ly said in a press re­lease. The ran­dom­ized Phase III study sought to com­pare Retev­mo to the mul­ti­k­i­nase in­hibitors cabozan­ti­nib or van­de­tanib.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER